Title
Patent and Trade Secret Rights in Pharma Registration
Law
Doh Administrative Order No. 2005-0001
Decision Date
Jan 3, 2005
Administrative Order No. 2005-0001 clarifies the responsibilities of the Department of Health, BFAD, IPO, and the court in ensuring the safety and quality of pharmaceutical products while protecting intellectual property rights, repealing a previous order and providing updated regulations.
A

Legal Framework for Drug Registration and Intellectual Property

  • Section 26(a), related to other sections of Republic Act No. 3720 (Food, Drugs and Devices and Cosmetic Act), and Republic Act No. 6675 (Generics Act) govern drug registration.
  • Administrative Order No. 67, series 1989 provides rules for pharmaceutical product registration.
  • Intellectual property (IP) issues such as patent rights, trademarks, and trade secrets are outside the regulatory scope of the Bureau of Food and Drugs (BFAD).
  • The appropriate jurisdiction for IP matters is the Intellectual Property Office (IPO) or courts of law.

Purpose and Objectives of the Revised Order

  • To revise and clarify policies combining the mandates of BFAD, IPO, and courts concerning pharmaceutical products and IP rights.
  • To reaffirm BFAD’s role in ensuring safety, efficacy, and quality of pharmaceutical products without adjudicating IP rights.
  • Defines "intellectual property rights" specifically as patents and trade secret rights over pharmaceutical products.

General Guidelines for Registration of Pharmaceutical Products

  • BFAD evaluates pharmaceutical product registration applications solely based on safety, quality, and efficacy.
  • Acceptance of applications by BFAD does not grant or imply any legal IP rights over the pharmaceutical product.
  • Applicants must submit a notarized affidavit of undertaking acknowledging possible cancellation of their Certificate of Product Registration (CPR) if they lack IP rights, and undertake to indemnify BFAD from third-party claims.
  • New applications for CPR must be posted on BFAD's website for at least 30 days including application number, generic name, brand name, and applicant’s name.
  • BFAD will notify any interested party asserting prior IP rights that such issues fall outside its jurisdiction and should be addressed to IPO or courts.
  • Notifications or postings do not cause suspension or delay in CPR processing unless BFAD is legally restrained by IPO or courts.
  • Annotations linking the CPR's effectivity to patent expiry are invalid and shall no longer be included or recognized.

Repealing Clause

  • Administrative Order No. 170, series 2004, and any other inconsistent issuances or guidelines are repealed or revoked.

Effectivity

  • The Order takes effect immediately after publication in two newspapers of general circulation.

Analyze Cases Smarter, Faster
Jur helps you analyze cases smarter to comprehend faster, building context before diving into full texts. AI-powered analysis, always verify critical details.